A commonly prescribed medication for attention-deficit hyperactivity disorder (ADHD) has been recalled nationwide due to concerns over its dissolution standards during laboratory testing. The medication in question is lisdexamfetamine dimesylate capsules, a generic alternative to the brand-name drug Vyvanse. This recall affects multiple dosage strengths of the stimulant medication, which is prescribed to improve focus in patients with ADHD and treat Binge Eating Disorder (BED). The FDA classified the action as a Class II recall, indicating potential temporary or medically reversible health issues. The affected lisdexamfetamine dimesylate capsules failed to dissolve properly during testing, but no specific details about the failure were provided. The recall includes 100-count bottles in seven dosage strengths ranging from 10 mg to 70 mg, with expiration dates between February and May 2026. Patients can identify affected bottles by checking the lot numbers printed on their medication packaging. The affected lots are as follows: Lisdexamfetamine Dimesylate Capsules, 10 mg (AD42468, Exp. Date 2/28/26, AD48705, Exp. Date 4/30/26); 20 mg (AD42469, Exp. Date 2/28/26, AD48707, Exp. Date 4/30/26); 30 mg (AD42470, Exp. Date 2/28/26, AD48708, Exp. Date 4/30/26); 40 mg (AD48709, Exp. Date 4/30/26, AD50894, Exp. Date 5/31/26); 50 mg (AD48710, Exp. Date 4/30/26, AD50895, Exp. Date 5/31/26); 60 mg (AD48711, Exp. Date 4/30/26, AD50896, Exp. Date 5/31/26); 70 mg (AD48712, Exp. Date 4/30/26, AD50898, Exp. Date 5/31/26). The FDA has not issued specific instructions for patients with recalled medication. If you have any affected bottles, contact your pharmacy or doctor for guidance on next steps.
